Novogene Korea
  • Novogene Korea
  • Genomics
    • Human Whole Genome Sequencing
    • Plant & Animal Whole Genome Sequencing
    • Microbial Whole Genome Sequencing
    • Whole Exome Sequencing
    • Plant & Animal De novo Sequencing
    • Microbial De novo Sequencing
    • Amplicon Sequencing
    • Shotgun Metagenomics Sequencing
    Transcriptomics
    • mRNA Sequencing
    • Total RNA Sequencing
    • Full-Length Transcriptome Sequencing
    • Whole Transcriptome Sequencing
    • Small RNA Sequencing
    • Circular RNA Sequencing
    • Metatranscriptome Sequencing
    • Prokaryotic RNA Sequencing
    Single Cell & Spatial Omics
    • Single Cell Gene Expression
    • Single Cell Immune Profiling Sequencing
    • Single Cell Long Read Transcriptome
    • Visium HD Spatial Gene Expression
    • Stereo-Seq Spatial Gene Expression
    • Xenium In Situ Spatial Transcriptome
    Epigenomics
    • Whole Genome Bisulfite Sequencing (WGBS)
    • Directed DNA Methylation Sequencing (DM-Seq) NEW
    • Reduced Representation Bisulfite Sequencing (RRBS)
    • Chromatin Immunoprecipitation Sequencing (ChIP-seq)
    • RNA Immunoprecipitation Sequencing (RIP-seq)
    • Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-seq)

    Premade Library

    • Sequencing Only (Illumina 플랫폼)
    • Sequencing Only (PacBio 플랫폼)
    Proteomics & Metabolomics
    • Olink Proteomics
    • Quantitative Proteomics (MS)
    • Untargeted Metabolomics (MS)
  • 프로모션프로모션
    • 플랫폼
    • 자동화 운송 플랫폼 (Falcon)
    • BI 분석툴 (NovoMagic)
    • Customer Service System (CSS)
    • 브로셔
    • 케이스 스터디
    • 웨비나
    • 블로그
    • 샘플준비 가이드라인
    • 커뮤니티
    • 암 연구
    • 면역 종양학
    • 농업
    • 환경
    • 식품
    • 인간 마이크로바이옴
    • 동물 & 식물 마이크로바이옴
    • 신약개발
    • 희귀 질환 연구
    • 회사소개
    • 글로벌 입지
    • 뉴스룸
    • 채용 정보
  • 문의하기문의하기
  1. Home
  2. Company
  3. Project SG100K- Singapore's National Precision Medicine Strategy

Project SG100K- Singapore's National Precision Medicine Strategy

Novogene is proud to be part of Project SG100K, Singapore’s National Precision Medicine Strategy to create Asia’s most comprehensive consented population study to further the population’s health and well-being. Paving the way for new drugs, faster diagnostics, and targeted treatments through precision medicine.

On 26th May 2022, Precision Health Research, Singapore (PRECISE), the central entity implementing Singapore’s National Precision Medicine (NPM) strategy, and Illumina, Inc (Illumina), a leader in genomics technology, announced a strategic partnership to sequence and analyze 100,000 Singaporean whole genomes (SG100K), to create for the first time, Asia’s most comprehensive consented population study.

NovogeneAIT Genomics Singapore Pte Ltd, one of the largest Next-Generation Sequencing service providers in Asia has been appointed by Illumina to carry out genome sequencing for 100,000 individuals in Singapore as part of the SG100K project.

According to Justin Lee, CEO of NovogeneAIT Genomics, “The National Precision Medicine (NPM) Project is a landmark initiative to transform healthcare by leveraging advancements in genomics. We are proud to carry out the sequencing for this project and contribute to our national effort to build up our population genomics database. We look forward to partnering with Illumina, a leader in genomics technology; and our local ecosystem partners to enhance our laboratory infrastructure, strengthen our local biotech talent and capabilities to better inform disease prevention strategies, drug development and treatment for the Asian population.”

Here’s the link to the full article regarding the PRECISE-Illumina partnership: https://www.npm.sg/precise-illumina-partnership-agreement/

Read this article for additional details about the Project 100k: https://www.straitstimes.com/singapore/health/dna-of-100000-singaporeans-to-be-mapped-to-further-populations-health

Watch the news about the sequencing and analysis of the DNA of 100,000 Singaporeans to improve health here: https://www.youtube.com/watch?v=X8K4mlUjx34&t=10s

서비스서비스 menu

고객지원고객지원 menu

기업정보기업정보 menu

서비스
WGSDe novo SeqAmplicon SeqShotgun MetagenomeDM-SeqmRNA-SeqSingle Cell Gene ExpressionVisium HDXenium In SituOlinkUntargeted Metabolomics
고객지원
노보매직CSSFalcon 플랫폼
기업정보
회사소개글로벌 입지플랫폼뉴스룸채용 정보문의하기
LinkedInLinkedIn hoverYouTubeYouTube hoverXX hoverMetaMeta hoverInstagramInstagram hover
Copyright © 2026 Novogene Co., Ltd. All Rights Reserved. 노보진의 한국 내 모든 서비스는 연구 목적 (Research Use Only, RUO) 으로만 제공됩니다. 사업자등록번호: 494-86-03792 | 판매자번호: 노보진코리아유한회사 | 대표자명: 리휘시앙 | 사업자주소: 서울시 강서구 마곡동 779-1번지 뉴브클라우드힐스 BT-230, 231호, 07790 | 전화번호: 02-2038-8036
Novogene Korea
  • Novogene Korea
  • Genomics
    • Human Whole Genome Sequencing
    • Plant & Animal Whole Genome Sequencing
    • Microbial Whole Genome Sequencing
    • Whole Exome Sequencing
    • Plant & Animal De novo Sequencing
    • Microbial De novo Sequencing
    • Amplicon Sequencing
    • Shotgun Metagenomics Sequencing
    Transcriptomics
    • mRNA Sequencing
    • Total RNA Sequencing
    • Full-Length Transcriptome Sequencing
    • Whole Transcriptome Sequencing
    • Small RNA Sequencing
    • Circular RNA Sequencing
    • Metatranscriptome Sequencing
    • Prokaryotic RNA Sequencing
    Single Cell & Spatial Omics
    • Single Cell Gene Expression
    • Single Cell Immune Profiling Sequencing
    • Single Cell Long Read Transcriptome
    • Visium HD Spatial Gene Expression
    • Stereo-Seq Spatial Gene Expression
    • Xenium In Situ Spatial Transcriptome
    Epigenomics
    • Whole Genome Bisulfite Sequencing (WGBS)
    • Directed DNA Methylation Sequencing (DM-Seq) NEW
    • Reduced Representation Bisulfite Sequencing (RRBS)
    • Chromatin Immunoprecipitation Sequencing (ChIP-seq)
    • RNA Immunoprecipitation Sequencing (RIP-seq)
    • Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-seq)

    Premade Library

    • Sequencing Only (Illumina 플랫폼)
    • Sequencing Only (PacBio 플랫폼)
    Proteomics & Metabolomics
    • Olink Proteomics
    • Quantitative Proteomics (MS)
    • Untargeted Metabolomics (MS)
  • 프로모션프로모션
    • 플랫폼
    • 자동화 운송 플랫폼 (Falcon)
    • BI 분석툴 (NovoMagic)
    • Customer Service System (CSS)
    • 브로셔
    • 케이스 스터디
    • 웨비나
    • 블로그
    • 샘플준비 가이드라인
    • 커뮤니티
    • 암 연구
    • 면역 종양학
    • 농업
    • 환경
    • 식품
    • 인간 마이크로바이옴
    • 동물 & 식물 마이크로바이옴
    • 신약개발
    • 희귀 질환 연구
    • 회사소개
    • 글로벌 입지
    • 뉴스룸
    • 채용 정보
  • 문의하기문의하기
  1. Home
  2. Company
  3. Project SG100K- Singapore's National Precision Medicine Strategy

Project SG100K- Singapore's National Precision Medicine Strategy

Novogene is proud to be part of Project SG100K, Singapore’s National Precision Medicine Strategy to create Asia’s most comprehensive consented population study to further the population’s health and well-being. Paving the way for new drugs, faster diagnostics, and targeted treatments through precision medicine.

On 26th May 2022, Precision Health Research, Singapore (PRECISE), the central entity implementing Singapore’s National Precision Medicine (NPM) strategy, and Illumina, Inc (Illumina), a leader in genomics technology, announced a strategic partnership to sequence and analyze 100,000 Singaporean whole genomes (SG100K), to create for the first time, Asia’s most comprehensive consented population study.

NovogeneAIT Genomics Singapore Pte Ltd, one of the largest Next-Generation Sequencing service providers in Asia has been appointed by Illumina to carry out genome sequencing for 100,000 individuals in Singapore as part of the SG100K project.

According to Justin Lee, CEO of NovogeneAIT Genomics, “The National Precision Medicine (NPM) Project is a landmark initiative to transform healthcare by leveraging advancements in genomics. We are proud to carry out the sequencing for this project and contribute to our national effort to build up our population genomics database. We look forward to partnering with Illumina, a leader in genomics technology; and our local ecosystem partners to enhance our laboratory infrastructure, strengthen our local biotech talent and capabilities to better inform disease prevention strategies, drug development and treatment for the Asian population.”

Here’s the link to the full article regarding the PRECISE-Illumina partnership: https://www.npm.sg/precise-illumina-partnership-agreement/

Read this article for additional details about the Project 100k: https://www.straitstimes.com/singapore/health/dna-of-100000-singaporeans-to-be-mapped-to-further-populations-health

Watch the news about the sequencing and analysis of the DNA of 100,000 Singaporeans to improve health here: https://www.youtube.com/watch?v=X8K4mlUjx34&t=10s

서비스서비스 menu

고객지원고객지원 menu

기업정보기업정보 menu

서비스
WGSDe novo SeqAmplicon SeqShotgun MetagenomeDM-SeqmRNA-SeqSingle Cell Gene ExpressionVisium HDXenium In SituOlinkUntargeted Metabolomics
고객지원
노보매직CSSFalcon 플랫폼
기업정보
회사소개글로벌 입지플랫폼뉴스룸채용 정보문의하기
LinkedInLinkedIn hoverYouTubeYouTube hoverXX hoverMetaMeta hoverInstagramInstagram hover
Copyright © 2026 Novogene Co., Ltd. All Rights Reserved. 노보진의 한국 내 모든 서비스는 연구 목적 (Research Use Only, RUO) 으로만 제공됩니다. 사업자등록번호: 494-86-03792 | 판매자번호: 노보진코리아유한회사 | 대표자명: 리휘시앙 | 사업자주소: 서울시 강서구 마곡동 779-1번지 뉴브클라우드힐스 BT-230, 231호, 07790 | 전화번호: 02-2038-8036
Privacy PolicyCookie Policy
Privacy PolicyCookie Policy